Cobra Biologics

UniTech Pharma appoints new CEO

Pressmeddelande   •   Aug 21, 2007 10:39 CEST

In the company's effort to expand its leadership with experienced professionals, it has engaged Mr. Peter Tamleht as Chief Executive Officer. Tamleht brings years of experience in organizational and business development, complementing his skills in operational and production management. He takes his new role as CEO after having worked with Pharmacia AB, Akzo Nobel and BE Group.

Departing Acting Managing Director and board member Tor Ökvist says, "Peter comes on board at an exciting time in UniTech Pharma's development. With a new pharmaceutical facility being added in Matfors, the company will benefit from his capabilities in managing growth - he understands the importance of meeting customer needs and the demands of building a well-functioning and thriving organization. We welcome Peter and wish him success."



About UniTech Pharma AB
UniTech Pharma AB provides manufacturing services of biopharmaceuticals and associated products for Scandinavian companies that need a strategic partner with a suite of capabilities including development and production of aseptic injection systems for pre-clinical, clinical and commercial use. The company's focus is to help customers find faster and more economical solutions to their protein/pharmaceutical production needs. Adding value to customer drug development, UniTech Pharma can assist in project management, optimize processes and produce pharmaceuticals.